报价延迟最少15分钟:2025/07/15 07:58 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
29.83
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.25/-3.92
|
|
企业价值
256.25M
|
| 资产负债 |
|
每股账面净值
-0.86
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
20.97M
|
|
每股收益
5.94
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/15 07:58 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3. |
